Key Segments:
By Disease
- Schizophrenia
- Bipolar Disorder
- Unipolar Depression
- Dementia
- Others
By Drug
- Risperidone
- Quetiapine
- Olanzapine
- Aripiprazole
- Brexpiprazole
- Paliperidone Palmitate
- Others
By Therapeutic Class
- First Generation
- Second Generation
- Third Generation
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
- US
- Canada
- Mexico
Europe
- Eastern Europe
- Poland
- Romania
- Hungary
- Turkey
- Rest of Eastern Europe
- Western Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Switzerland
- Austria
- Rest of Western Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Vietnam
- Singapore
- Australia
- Rest of Asia Pacific
Middle East & Africa
Middle East
- UAE
- Egypt
- Saudi Arabia
- Qatar
- Rest of the Middle East
Africa
- Nigeria
- South Africa
- Rest of Africa
Latin America
- Brazil
- Argentina
- Colombia
- Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Product Analysis
- Criss-Cross segment analysis (e.g. Product X Application)
- Product Matrix which gives a detailed comparison of the product portfolio of each company
- Geographic Analysis
- Additional countries in any of the regions
- Company Information
- Detailed analysis and profiling of additional market players (Up to five)
Frequently Asked Questions
Ans: The Antipsychotic Drugs Market was valued at USD 17.69 billion in 2024 and is expected to reach USD 29.23 billion by 2032, growing at a CAGR of 6.53% from 2025-2032.
Ans: The growth is primarily driven by the increasing prevalence of mental health disorders, with 21% of adults suffering from mental illness in 2024.
Ans: Second-generation antipsychotics dominated the market with a revenue share of about 61% in 2024 due to their efficacy and safety profiles.
Ans: Schizophrenia accounted for the highest revenue share of about 42% in the antipsychotic drugs market in 2024.
Ans: Common side effects include weight gain, dry mouth, dizziness, and sexual dysfunction, which can affect patient compliance.